Silence Therapeutics Shares Rise on $20 Cash Acquisition Agreement

The offer and the trading move

Silence Therapeutics announced on October 19, 2026, that it had agreed to be acquired by Merck KGaA, Darmstadt, Germany, for $20.00 in cash per American depositary share (ADS). SLN closed that U.S. session at $19.58, up 125.58% from $8.68 on October 16. The agreement was signed October 18. The announced price and the same-day move closely align, making the acquisition terms the direct explanation for the repricing. The sources do not establish every trader’s reason for buying or selling.

The announced consideration values Silence at approximately $1.3 billion in equity and $1.1 billion in enterprise value. Each ADS represents three ordinary shares, with stated consideration of $6.6667 per ordinary share. Silence said the $20.00 ADS price represented a 130% premium to its October 16 closing price and an 82% premium to its 30-day volume-weighted average price of $10.99. Those terms gave investors a specified cash payout against which to assess the stock’s previous trading price.

Trading volume rose to 71,918,760 ADSs on October 19 from 1,131,128 on October 16. The closing price remained $0.42, or 2.1%, below the proposed payout. That gap shows the traded share price was below the conditional cash consideration; it does not, by itself, measure the probability that the acquisition will close. The expected time until payment and uncertainty about the transaction can also affect the price.

The asset behind the transaction

Silence develops short interfering RNA medicines and remains a clinical-stage company. Merck KGaA identified divesiran, an investigational treatment for polycythemia vera, as a principal asset in its acquisition announcement. Merck reported that divesiran’s Phase 2 SANRECO study met its primary endpoint, with an 88% responder rate versus 19% for placebo, and described the candidate as Phase 3-ready. These are Merck’s reported study results and development characterization. Divesiran’s Phase 3 results, development timetable and regulatory outcome remain unknown.

The asset helps explain the acquirer’s stated interest, while the agreed cash consideration explains the immediate change in SLN’s near-term valuation basis. Investors could compare a proposed $20.00 payout with the $8.68 pre-announcement close rather than assess the company solely through its independent development prospects. Merck KGaA, Darmstadt, Germany, is distinct from the U.S. company that uses the Merck name. Neither company has established that divesiran is already best-in-class; their descriptions use qualified language such as “potentially best-in-class.”

Conditions before shareholders receive cash

Silence’s board unanimously approved the transaction, and securityholders representing approximately 14% of voting power agreed to support it. That commitment does not secure approval. The planned U.K. scheme of arrangement requires shareholder votes, sanction by the High Court of Justice of England and Wales, and regulatory clearance, including U.S. and German antitrust steps. The SEC filing specifies separate thresholds for the scheme meeting and general meeting. The agreement has no financing condition, but the other conditions still govern whether the proposed payment occurs.

The companies expect to close in the first quarter of 2027. The filing provides for specified termination rights that generally begin if the deal has not closed by April 30, 2027, subject to a limited extension. Neither date guarantees completion. Silence has said it will provide an SEC proxy statement and scheme documentation; those materials should supply the voting timetable and further transaction information. Shareholder-vote results, antitrust outcomes, court sanction and any closing announcement will establish whether the remaining steps have been completed.

Silence described the transaction as following a “competitive sale process,” but its announcement did not disclose competing bids or their terms. An alternative proposal remains uncertain. The agreement restricts solicitation of alternatives, with exceptions and a $13 million termination fee in specified circumstances. The October 19 close therefore reflects a stock trading near an announced cash offer whose completion and timing remain conditional.

MacroShed Markets is informational analysis, not investment advice.